Apoptosis and proliferation differences between CD34+ and CD34- leukemic subpopulations in childhood acute leukemia

Hematology

Volumn 12, Issue 5, 2007, Pages 403-407

  Shman, Tatsiana V ^a   Savitski, Valery P ^a   Fedasenka, Uladzimir U ^a   Aleinikova, Olga V ^a  

^a Belarusian Research Center for Pediatric Oncology and Hematology   (Belarus)

Author keywords

Acute leukemia; Apoptosis; Cell cycle; Immunophenotypic heterogeneity

Indexed keywords

CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CD34 SELECTION; CELL HETEROGENEITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD34; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CHILD; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 34748846931     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701393758     Document Type: Article

References (14)

1. Ravindranath, Y. (2003) Recent advances in pediatric lymphoblastic and myeloid leukemia. Curr Opin Oncol, 15, pp. 23-35.
2. Reya, T., Morrison, SJ, Clarke, MF and Weissman, IL (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, pp. 105-111.
3. Poot, M., Gibson, LL and Singer, L. (1997) Detection of apoptosis in live cells by Mito Tracker Red CMXRos and SYTO dye flow cytometry. Cytometry, 27, pp. 358-364.
4. Ormerod, MG (1994) Analysis of DNA-general methods. Flow cytometry. A practical approach, pp. 119-135. Oxford University Press, New York
5. Hrusak, O. and Porwit-MacDonald, A. (2002) Antigen expression patterns reflecting genotype of acute leukemias. Leukemia, 16, pp. 1233-1258.
6. Oyan, AM, Bo, TH, Jonassen, I., Ulvestad, E., Gjertsen, BT, Kalland, K-H and Bruserud, O. (2005) CD34 expression in native human acute myelogeneous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry Part B (Clinical Cytometry), 64, pp. 18-27.
7. Langebrake, C., Brinkmann, I., Teigler-Schlegel, A., Creutzig, U., Griesinger, F., Puhlmann, U. and Reinhardt, D. (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry Part B (Clinical Cytometry), 63, pp. 1-9.
8. Borowitz, MJ, Pullen, DJ, Winick, N., Martin, PL, Bowman, WP and Camitta, B. (2005) Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group. Cytometry part B (Clinical Cytometry), 68, pp. 18-24.
9. Meleshko, A., Savitski, V., Shman, T. and Aleinikova, O. (2006) Immunophenotypically heterogeneous acute T-lymphoblastic leukemia has invariable immunogenotype: Analysis of two cases. J Pediatr Hematol Oncol, 28, pp. 50-52.
10. Holleman, A., Boer, M Den, Kazemier, KM, Janka-Schaub, GE and Pieters, R. (2003) Resistance to different classes of drugs is associated with impaired apoptosis in childhood ALL. Blood, 102, pp. 4536-4541.
11. van Stijn, A., van der Pol, MA, Kok, A., Bontje, PM, Roemen, GMJM, Beelen, RHJ, Ossenkoppele, GJ and Schuurhuis, GJ (2004) Differences between the CD34+ and CD34- blast compartment in apoptosis resistance in acute myeloid leukemia. Haematologica, 88, pp. 497-508.
12. Stanke, K., Eckhoff, S., Mohr, A., Meyer, LH and Debatin, K-M (2003) Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: Selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia, 17, pp. 2130-2139.
13. Holtz, MS, Forman, SJ and Bhatia, R. (2005) Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia, 19, pp. 1034-1041.
14. Preisler, HD, Raza, A., Bonomi, P., Taylor, S., LaFolette, S., Leslie, W. and Lincoln, S. (1997) Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest, 15, pp. 358-368.